VRDN Q1 2026 Earnings NarrowerthanExpected Loss as Viridian Advances Clinical Pipeline Castle Biosciences Q1 2026 Earnings Narrowly Beats EPS Estimates but Stock Declines TT Q1 2026 Earnings EPS Beats Estimates Stock Edges Higher SRBK Q3 2025 Earnings Positive EPS of 006 Stock Advances 243 GBLI Q1 2026 Earnings EPS Falls Short of Estimates as Underwriting Results Weigh CVNA Q1 2026 Earnings EPS Beats Estimates by Over 12 Stock Surges 6